NEW YORK (360Dx) — Genspeed announced today that it has partnered with Danish medical technology firm Virogates to develop a rapid point-of-care test for medical risk classification.
According to Rainbach, Austria-based Genspeed, the test will be designed to detect C-reactive protein, a biomarker of inflammation, and suPAR, a protein biomarker of inflammation and immune system activity, from a finger prick within 10 minutes. Results from the test — which will combine Genspeed's microfluidic and optoelectronic testing technology and Virogates' suPARnostic suPAR testing system and reagents — can be used to determine whether a patient requires hospital admission.
Specific terms of the deal were not disclosed.
"We believe the combination of suPARnostic and Genspeed technology will provide fast, easy to obtain, and reliable results in both selected hospitals and in outpatient settings," Virogates CEO Jakob Knudsen said in a statement. "The product will enable patients to be tested at an earlier stage than today and this will improve the risk assessment of the patient significantly."